Riding interest in large investors in the health sector, five pharmaceutical companies tapped the market for the initial public offering (IPO) for the next few weeks to collect more than Rs 8,000 Crore.
This list includes the IPO RS 4,000 Crore by Bain Permaking Pharma mode, the problem of Rs 1,500 Crore by Vijaya Diagnostic Center, Diagnostic Diagnostic Company Krsnaa (RS 1,200 Crore) and Mumbai-Based Mass Medicine Makers (RS 1,200) Crore), and Contract Development Formulation Formulations Manufacturer (CDMO) Problems RS 400 Crore Windlass Biotech.
Investment bankers estimate these five companies to collect more than Rs 8,300 Crore through public offers this month.
According to data available with the stock market, so far this fiscal, 12 companies have raised RS 27,000 crore from iOS, and more crore problems in the pipe.
The whole FY21 only saw 30 IPO increasing Rs 31,277 Crore. Apart from this pharmaceutical firm, Devyani International and Exxaro tiles opened on August 4 and the problems of consumer-focused companies such as Paytm, Mobikwik, Polikebazaar, Cartrade, Delhivery, and Nykaa soon.
According to marketmen as many as 40 problems marched for the rest of the year by searching for Rs 70,000 Crore.
While 12 companies raise Rs 27,052 Crore through the IPO in the first four months of the current fiscal, and PowerGrid Invit has mopped RS 7,735 Crore through the IPO.
As with this, the whole FY21 only saw 30 problems raising Rs 31,277 Crore, RS 20,352 Crore by 13 companies in FY20, 14 companies raised Rs 14,719 Crore at FY19 and 45 IPO main boards collectively mobilized RS 82.109 Crore at FY18.
That there is a tremendous appetite clear investor from the problem of the Chartan Pharma Ring Ring Tatva, Gref Infraprathy, Clean Science & Technology, Shyam Metallics & Energy, Indian Pesticides, Dodla Dairy, Glenmark Life Sciences and Zomato Subscribe – 29 times up to 180 times.
In fact, pharmaceutical shares have been in the center of attention because the pandemic broke out last year and the BSE health index had been powerful at a long time.
The health list has also been well done well, as indicated by RS 2,144-Crore KimS Hospitals Issue which is because the list rose more than 45 percent.
And the problem of the life science of Glenmark Rs 1,514-Crore, closed on July 29, accepts the number of most retail applications since 2008.
Pharmaceutical companies also get from Tailwinds to the fire market, and China plus one strategy where India is the main focus.
“The launch of new products, aging population and settling lifestyles leads to increased prevalence of chronic diseases, new drug discovery methods, and increased use of drugs are some of the main growth drivers for this industry,” according to an analyst with an analyst with a broker. Work on some of these problems.
Some of these companies are also regulated to benefit from their proven capabilities in making contracts, which are regulated to benefit from increased outsourcing R & D in the industry, other i-banker words.
Windlas Biotech, one of the leading CDMO focuses on the chronic therapy segment, and has strong and long-term relationships with leading pharmaceutical companies such as Pfizer, Sanofi, Cadila, Zydus Healthcare, Emcure Pharmaceuticals, and Pharmacy Intas, and Intas, and Thursday launch The RS 400 Crore problem opened on August 4.
This will be the first CDMO pharmaceutical formulation for GO PUBLIC.
The IPO results will be used to increase the capacity of Dehradun II & IV plants.
It has two more cities of Uttarakhand. The latest example of the boom in the Pharma and Health Care is a matter of life science of Glenmark who subscribes to 44.17 times with a qualified institutional buyer offer for 36.97 times, non-institutional investors 122.54 times and retail 14.63 times.
